Literature DB >> 23218564

C-reactive protein is elevated in schizophrenia.

Faith Dickerson1, Cassie Stallings, Andrea Origoni, Crystal Vaughan, Sunil Khushalani, Shuojia Yang, Robert Yolken.   

Abstract

BACKGROUND: Increased levels of inflammatory markers have been reported in schizophrenia, but few studies have examined levels of high sensitivity C-reactive protein (CRP), a non-specific inflammatory marker.
METHODS: Levels of high sensitivity CRP were measured in individuals with schizophrenia, bipolar disorder, and non-psychiatric controls. Linear regression analyses were used to compare the CRP levels among the three groups adjusting for demographic and clinical variables. Logistic regression analyses were used to determine the odds ratios associated with elevated levels of CRP, defined as >=75th and 90th percentile in the controls.
RESULTS: The sample consisted of 715 individuals: 295 with schizophrenia, 192 with bipolar disorder, and 228 without a psychiatric disorder. The levels of CRP in the schizophrenia group, but not in the bipolar disorder group, were significantly increased compared to controls adjusting for age, gender, race, maternal education, smoking status, and Body Mass Index (BMI) (t=3.78, p=<.001). The individuals with schizophrenia had significantly increased odds of having elevated levels of CRP relative to both the 75th and 90th percentile levels of the controls adjusting for the same covariates (OR 1.79, 95% CI 1.14, 2.82; p=.012; OR 2.76, 95% CI 1.58, 4.83, p=<.001). In the multivariate linear and logistic regression analyses, levels of CRP were also associated with BMI and female gender.
CONCLUSIONS: Individuals with schizophrenia may be at risk for the adverse health consequences associated with elevated CRP in the overall population. Trials of interventions directed at lowering the level of CRP and other inflammatory markers are indicated.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218564     DOI: 10.1016/j.schres.2012.10.041

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  46 in total

Review 1.  The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders.

Authors:  Emily G Severance; Dag Tveiten; Lief H Lindström; Robert H Yolken; Karl L Reichelt
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

2.  Joint evaluation of serum C-Reactive Protein levels and polygenic risk scores as risk factors for schizophrenia.

Authors:  Vishwajit L Nimgaonkar; Faith Dickerson; Jennie G Pouget; Kodavali Chowdari; Colm O'Dushlaine; Joel Wood; Lambertus Klei; Bernie Devlin; Robert Yolken
Journal:  Psychiatry Res       Date:  2017-12-21       Impact factor: 3.222

3.  The extent of diffusion MRI markers of neuroinflammation and white matter deterioration in chronic schizophrenia.

Authors:  Ofer Pasternak; Carl-Fredrik Westin; Brian Dahlben; Sylvain Bouix; Marek Kubicki
Journal:  Schizophr Res       Date:  2014-08-10       Impact factor: 4.939

4.  Inflammatory Markers in Recent Onset Psychosis and Chronic Schizophrenia.

Authors:  Faith Dickerson; Cassie Stallings; Andrea Origoni; Jennifer Schroeder; Emily Katsafanas; Lucy Schweinfurth; Christina Savage; Sunil Khushalani; Robert Yolken
Journal:  Schizophr Bull       Date:  2015-08-19       Impact factor: 9.306

Review 5.  The known and missing links between Toxoplasma gondii and schizophrenia.

Authors:  Hany M Elsheikha; Dietrich Büsselberg; Xing-Quan Zhu
Journal:  Metab Brain Dis       Date:  2016-04-04       Impact factor: 3.584

6.  Shared Immune and Repair Markers During Experimental Toxoplasma Chronic Brain Infection and Schizophrenia.

Authors:  Jakub Tomasik; Tracey L Schultz; Wolfgang Kluge; Robert H Yolken; Sabine Bahn; Vern B Carruthers
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

7.  Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study.

Authors:  Emily G Severance; Kristin L Gressitt; Cassie R Stallings; Emily Katsafanas; Lucy A Schweinfurth; Christina L G Savage; Maria B Adamos; Kevin M Sweeney; Andrea E Origoni; Sunil Khushalani; Faith B Dickerson; Robert H Yolken
Journal:  Brain Behav Immun       Date:  2016-11-18       Impact factor: 7.217

8.  Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia.

Authors:  Emily G Severance; Kristin L Gressitt; Cassie R Stallings; Andrea E Origoni; Sunil Khushalani; F Markus Leweke; Faith B Dickerson; Robert H Yolken
Journal:  Schizophr Res       Date:  2013-06-06       Impact factor: 4.939

Review 9.  Biomarkers in psychosis: an approach to early identification and individualized treatment.

Authors:  Heline Mirzakhanian; Fiza Singh; Kristin S Cadenhead
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

10.  Cardiovascular disease risk in schizophrenia patients: a case control study.

Authors:  Kedar B Joshi; Anup Nillawar; A P Thorat
Journal:  J Clin Diagn Res       Date:  2013-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.